Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Medacta Group S.A. (MOVE.SW)
CHF138.00
+0.40 (+0.29%)
CH SIX Healthcare Medical - Devices
Address
Strada Regina, 34 6874
Castel San Pietro, CH
Castel San Pietro, CH
CEO
Francesco Siccardi
Website
medacta.com
IPO
2019-04-03
ISIN CH0468525222
Also trades on
London Stock Exchange · 0A05.L (CHF)
Other OTC · MEDGF (USD)
Swiss Exchange · MOVE.SW (CHF)
Description
Medacta Group S.A. is a worldwide enterprise specializing in the design, production, and distribution of medical devices for both orthopedic and neurosurgical applications. Operating across Europe, North America, the Asia-Pacific region, and numerous other international markets, the company delivers specialized solutions. These include custom kinematic models and three-dimensional planning software, which are employed in various surgical procedures such as those for the hip, knee, and shoulder, as well as in sports medicine and spinal treatments. The firm, established in 1958, maintains its primary corporate office in Castel San Pietro, Switzerland.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CHF138.00
+0.40 (+0.29%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
17.0K
Beta
0.99
Float Shares
6.08M
Free Float %
30.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.43% | -3.11% | +1.13% | -10.16% | -7.49% | -9.60% | +6.23% | +27.86% | +15.48% | +49.17% | +49.17% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
138.00
DCF (Unlevered)
33.86
-75.5%
DCF (Levered)
113.13
-18.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
80% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
7.19
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+16.5% ★ Q4'25: +33.1% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%+31.8% ★ Q4'25: +97.8% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%+8.9% ★ Q4'25: +3.6% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%+16.8% ★ Q4'25: +16.2% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%+14.0% ★ Q4'25: +24.4% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%+0.3% Q4'25: +0.6% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×1.38× Q4'25: 0.70× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 4 EPS Ana. |
Dec 2027 5 Rev. Ana. 4 EPS Ana. |
Dec 2028 5 Rev. Ana. 5 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
310.62M
est: 335.54M (-7.4%)
|
302.49M
est: 325.35M (-7.0%)
|
363.13M
est: 374.83M (-3.1%)
|
437.12M
est: 426.88M (+2.4%)
|
510.78M
est: 564.59M (-9.5%)
|
590.58M
est: 588.51M (+0.4%)
|
688.27M
est: 684.50M (+0.6%)
|
751.45M
746.74M – 763.42M
+9.8% YoY
|
844.37M
827.61M – 862.23M
+12.4% YoY
|
939.95M
927.31M – 957.52M
+11.3% YoY
|
1.06B
1.04B – 1.08B
+12.4% YoY
|
| EBITDA |
73.83M
est: 86.64M (-14.8%)
|
81.96M
est: 39.87M (+105.5%)
|
97.82M
est: 48.27M (+102.6%)
|
106.96M
est: 54.23M (+97.2%)
|
119.64M
est: 167.81M (-28.7%)
|
160.51M
est: 174.36M (-7.9%)
|
190.55M
est: 203.45M (-6.3%)
|
223.35M
221.95M – 226.91M
+9.8% YoY
|
250.97M
245.99M – 256.28M
+12.4% YoY
|
279.38M
275.62M – 284.60M
+11.3% YoY
|
314.06M
309.84M – 319.94M
+12.4% YoY
|
| EBIT |
40.10M
est: 55.66M (-28.0%)
|
52.84M
est: 18.90M (+179.6%)
|
67.08M
est: 22.88M (+193.2%)
|
69.46M
est: 25.70M (+170.2%)
|
76.51M
est: 92.91M (-17.6%)
|
95.28M
est: 96.53M (-1.3%)
|
115.65M
est: 112.64M (+2.7%)
|
123.66M
122.88M – 125.63M
+9.8% YoY
|
138.95M
136.19M – 141.89M
+12.4% YoY
|
154.68M
152.60M – 157.57M
+11.3% YoY
|
173.88M
171.54M – 177.13M
+12.4% YoY
|
| Net Income |
11.86M
est: 47.12M (-74.8%)
|
37.09M
est: 11.43M (+224.6%)
|
51.52M
est: 13.83M (+272.5%)
|
46.25M
est: 49.77M (-7.1%)
|
47.36M
est: 58.31M (-18.8%)
|
72.89M
est: 76.23M (-4.4%)
|
96.12M
est: 102.51M (-6.2%)
|
100.33M
96.20M – 104.46M
-2.1% YoY
|
115.61M
110.81M – 120.40M
+15.2% YoY
|
135.58M
129.46M – 141.70M
+17.3% YoY
|
163.03M
160.18M – 167.00M
+20.3% YoY
|
| SGA |
176.37M
est: 161.49M (+9.2%)
|
155.28M
est: 150.13M (+3.4%)
|
182.39M
est: 181.76M (+0.3%)
|
220.22M
est: 204.21M (+7.8%)
|
252.47M
est: 265.07M (-4.8%)
|
231.89M
est: 277.02M (-16.3%)
|
312.78M
est: 321.36M (-2.7%)
|
352.80M
350.59M – 358.42M
+9.8% YoY
|
396.42M
388.55M – 404.81M
+12.4% YoY
|
441.29M
435.36M – 449.54M
+11.3% YoY
|
496.08M
489.41M – 505.35M
+12.4% YoY
|
| EPS |
0.59
est: 2.36 (-75.0%)
|
1.85
est: 1.60 (+15.8%)
|
2.58
est: 3.14 (-17.7%)
|
2.32
est: 2.86 (-19.0%)
|
2.37
est: 2.92 (-19.0%)
|
3.65
est: 3.80 (-3.9%)
|
4.81
est: 4.82 (-0.1%)
|
5.07
4.81 – 5.22
+5.3% YoY
|
5.84
5.54 – 6.02
+15.2% YoY
|
6.85
6.47 – 7.08
+17.2% YoY
|
8.15
8.01 – 8.35
+19.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
201.60M
OE per share TTM
10.09
Owner's Yield
7.00%
Maintenance CapEx ratio
63.84%
Maint CapEx / Avg PPE
52.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 62 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Global X - Aging Population ETF AGNG | 0.27% | 233.8K | 0.50% |
| 2 | iShares Ageing Population UCITS ETF AGED.L | 0.09% | 803.0K | 0.40% |
| 3 | iShares MSCI Europe Small-Cap ETF IEUS | 0.07% | 119.0K | 0.41% |
| 4 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.07% | 2.22M | 0.30% |
| 5 | iShares Core SPI(R) ETF (CH) CHSPI.SW | 0.04% | 3.14M | 0.10% |
| 6 | Avantis International Small Cap Equity ETF AVDS | 0.04% | 133.5K | 0.30% |
| 7 | Schwab International Small-Cap Equity ETF SCHC | 0.04% | 2.17M | 0.06% |
| 8 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.03% | 74.3K | 0.83% |
| 9 | iShares MSCI EAFE Small-Cap ETF SCZ | 0.03% | 4.47M | 0.40% |
| 10 | Dimensional - International Small Cap ETF DFIS | 0.03% | 1.73M | 0.39% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
60.6K
Shares Outstanding
19.91M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Francesco Siccardi | Chief Executive Officer | 2M | — |
| Alberto Siccardi | Founder & Non Executive Chairman | 325.4K | — |
| Antonio Di Brino | Group Vice President of Finance & Tax | — | — |
| Asif Hussain | Chief People Officer | — | male |
| Corrado Farsetta | Chief Financial Officer | — | male |
| Donato Cortesi | Secretary of the Board | — | — |
| Filippo Cappelli | Head of IT | — | — |
| Giovanni Niccolo Galli | Chief Commercial Officer | — | male |
| Massimiliano Bernardoni | Chief Innovation Officer | — | male |
| Alessandro Siccardi | Chief Supply Chain Officer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MOVE.SW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
